CRISPR/Cas9 screening identified MCL1 as a critical vulnerability in palbociclib-induced senescent colorectal cancer cells. The CDK4/6 inhibitor palbociclib creates senescent cancer cells that upregulate ZHX2 and MCL1, leading to apoptosis resistance and PD-L1 expression that suppresses CD8+ T cell function. Combining palbociclib with MCL1 inhibitors activated both intrinsic and extrinsic apoptotic pathways, eliminating these problematic senescent cells while reducing immunosuppressive PD-L1-positive populations.
This represents a sophisticated evolution in cancer senotherapy—using senescence-inducing drugs followed by targeted elimination of the senescent cells themselves. The approach addresses a fundamental challenge in oncology: therapy-induced senescence often creates drug-resistant, inflammatory cell populations that can promote tumor recurrence. The dual immune benefit—direct senescent cell clearance plus enhanced CD8+ T cell activity—suggests broader applications beyond colorectal cancer. However, the complexity of sequential dosing and potential off-target effects of MCL1 inhibition on healthy cells warrant careful clinical translation. This targeted senolytic strategy could transform how we deploy senescence-inducing therapies across cancer types.